Search research articles
Contact Us
Filters
Showing results (731-740 of 962) with videos related to
Page
of 97
Sort By:
JACC. Cardiovascular Interventions
|
October 12, 2019
Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention
Hector M Garcia-Garcia, Eugène P McFadden, Clemens von Birgelen, et al.
Journal of the American Heart Association
|
March 9, 2022
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI
Benjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
Journal of the American College of Cardiology
|
May 14, 2021
Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials
Lawrence A Leiter, Deepak L Bhatt, Darren K McGuire, et al.
Journal of the American College of Cardiology
|
February 7, 2025
Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials
Sina Rashedi, Mohammad Keykhaei, Alyssa Sato, et al.
Nature Medicine
|
August 6, 2024
Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials
Nicholas A Marston, James P Pirruccello, Giorgio E M Melloni, et al.
Circulation
|
November 12, 2019
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial
Amy Damask, P Gabriel Steg, Gregory G Schwartz, et al.
Circulation
|
November 5, 2020
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses
Benjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
European Heart Journal
|
October 8, 2015
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial
Giulia Magnani, Robert F Storey, Gabriel Steg, et al.
European Heart Journal. Quality of Care & Clinical Outcomes
|
August 24, 2022
The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial
Andre Lamy, John Eikelboom, Wesley Tong, et al.
American Heart Journal
|
June 5, 2017
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial
Freddy Abnousi, Vandana Sundaram, Celina M Yong, et al.
Page
of 97
Search research articles
Search
Showing results (731-740 of 962) with videos related to
Sort By:
Page
of 97
JACC. Cardiovascular Interventions
|
October 12, 2019
Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention
Hector M Garcia-Garcia, Eugène P McFadden, Clemens von Birgelen, et al.
Journal of the American Heart Association
|
March 9, 2022
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI
Benjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
Journal of the American College of Cardiology
|
May 14, 2021
Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials
Lawrence A Leiter, Deepak L Bhatt, Darren K McGuire, et al.
Journal of the American College of Cardiology
|
February 7, 2025
Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials
Sina Rashedi, Mohammad Keykhaei, Alyssa Sato, et al.
Nature Medicine
|
August 6, 2024
Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials
Nicholas A Marston, James P Pirruccello, Giorgio E M Melloni, et al.
Circulation
|
November 12, 2019
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial
Amy Damask, P Gabriel Steg, Gregory G Schwartz, et al.
Circulation
|
November 5, 2020
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses
Benjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
European Heart Journal
|
October 8, 2015
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial
Giulia Magnani, Robert F Storey, Gabriel Steg, et al.
European Heart Journal. Quality of Care & Clinical Outcomes
|
August 24, 2022
The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial
Andre Lamy, John Eikelboom, Wesley Tong, et al.
American Heart Journal
|
June 5, 2017
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial
Freddy Abnousi, Vandana Sundaram, Celina M Yong, et al.
Page
of 97